Drug trial finds no benefit in combination therapy for heart failure with reduced ejection fraction
Newly discovered epigenetic regulatory mechanisms involved in multiple myeloma growth
17 May 2021Prenatal detection of heart defects lower in rural, poor areas and among Hispanic women
17 May 2021Drug trial finds no benefit in combination therapy for heart failure with reduced ejection fraction
Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to new data presented at the American College of Cardiology’s 70th Annual Scientific Session.
